In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).

"Competing interests D. C. Loconte, V. Grossi, S. Di Tommaso, C. Ranieri, P. Sanese, R. Bagnulo, G. Forte, F.C. Susca, A. Peserico, A. De Luisi, A. Bartuli, A. Selicorni, D. Melis, M.Lerone, A.D. Praticò, M. Ruggieri, C. Simone, N. Resta declare that no competing interest exist. G. Abbadessa and Y. Yu are employees of ArQule, Inc."

"Funding sources This study was partially supported by the Italian Health Ministry [Ministero della Salute: RF-2011-02352088 to Dr. Nicoletta Resta]; by the University Fundings [Fondi D’Ateneo/Conto Terzi] from the University of Bari “Aldo Moro” [to Dr. Nicoletta Resta]; by an ‘Investigator Grant 2014’ from the Italian Association for Cancer Research (AIRC) [IG15696 to Dr. Cristiano Simone]; by a FIRB-Futuro in Ricerca RBFR12VP3Q_003 from the Italian Ministry of School, University and Research [MIUR: to Dr. Cristiano Simone]; by a grant from “Giovani Ricercatori” 2011-2012’ GR-2011-02351968 from the Italian MOH [to Dr. Cristiano Simone]; and by a grant from “Ricerca Finalizzata” 2011-2012’ [RF-2011-02352088 from the Italian MOH to Dr. Cristiano Simone]."